Skip to main content
SpringerLink
Log in

Proteomics associated with coronary high-risk plaques by optical coherence tomography

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Biomarkers are widely used for the diagnosis and monitoring of cardiovascular disease. However, markers for coronary high-risk plaques have not been identified. The aim of this study was to identify proteins specific to coronary high-risk plaques. Fifty-one patients (71.2 ± 11.1 years, male: 66.7%) who underwent intracoronary optical coherence tomography imaging and provided blood specimens for proteomic analysis were prospectively enrolled. A total of 1470 plasma proteins were analyzed per patient using the Olink® Explore 1536 Reagent Kit. In patients with thin-cap fibroatheroma, the protein expression of Calretinin (CALB2), Corticoliberin (CRH) and Alkaline phosphatase, placental type (ALPP) were significantly increased, while the expression of Neuroplastin (NPTN), Folate receptor gamma (FOLR3) and Serpin A12 (SERPINA12) were significantly decreased. In patients with macrophage infiltration, the protein expressions of Fatty acid-binding protein, intestinal (FABP2), and Fibroblast growth factor 21 (FGF21) were significantly decreased. In patients with lipid-rich plaques, the protein expression of Interleukin-17 C (IL17C) was significantly increased, while the expression of Fc receptor-like protein 3 (FCRL3) was significantly decreased. These proteins might be useful markers in identifying patients with coronary high-risk plaques.

Clinical Trial Registration: https://www.umin.ac.jp/ctr/, UMIN000041692

Graphical abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

ACS:

Acute coronary syndromes

FCT:

Fibrous cap thickness

OCT:

Optical coherence tomography

SAP:

Stable angina pectoris

TCFA:

Thin-cap fibroatheroma

References

  1. Tsao CW, Aday AW, Almarzooq ZI et al (2022) Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation 145:E153–E639. https://doi.org/10.1161/CIR.0000000000001052

    Article  PubMed  Google Scholar 

  2. Stone GW, Maehara A, Lansky AJ et al (2011) A prospective natural-history study of coronary atherosclerosis. N Engl J Med 364:226–235. https://doi.org/10.1056/nejmoa1002358

    Article  CAS  PubMed  Google Scholar 

  3. Xing L, Higuma T, Wang Z et al (2017) Clinical significance of lipid-rich plaque detected by optical coherence tomography a 4-Year follow-up study. J Am Coll Cardiol 69:2502–2513

    Article  PubMed  Google Scholar 

  4. Al-Lamee R, Mintz GS (2021) What are the prospects and clinical implications of vulnerable plaque? Eur Heart J 42:4680–4682. https://doi.org/10.1093/eurheartj/ehab521

    Article  PubMed  Google Scholar 

  5. Aguirre AD, Arbab-Zadeh A, Soeda T, Fuster V, Jang IK (2021) Optical coherence tomography of plaque vulnerability and rupture: JACC focus seminar part 1/3. J Am Coll Cardiol 78:1257–1265. https://doi.org/10.1016/j.jacc.2021.06.050

    Article  PubMed  PubMed Central  Google Scholar 

  6. Araki M, Park SJ, Dauerman HL et al (2022) Optical coherence tomography in coronary atherosclerosis assessment and intervention. Nat Rev Cardiol 19:684–703. https://doi.org/10.1038/s41569-022-00687-9

    Article  PubMed  PubMed Central  Google Scholar 

  7. Arab S, Gramolini AO, Ping P et al (2006) Cardiovascular proteomics. Tools to develop novel biomarkers and potential applications. J Am Coll Cardiol 48:1733–1741. https://doi.org/10.1016/j.jacc.2006.06.063

    Article  CAS  PubMed  Google Scholar 

  8. Lam MPY, Ping P, Murphy E (2016) Proteomics research in cardiovascular medicine and biomarker discovery. J Am Coll Cardiol 68:2819–2830

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Stakhneva EM, Striukova EV, Ragino YI (2021) Proteomic studies of blood and vascular wall in atherosclerosis. Int J Mol Sci 22:13267. https://doi.org/10.3390/ijms222413267

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Palstrøm NB, Matthiesen R, Rasmussen LM, Beck HC (2022) Recent developments in clinical plasma proteomics—applied to cardiovascular research. Biomedicines 10:162. https://doi.org/10.3390/biomedicines10010162

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Chiorescu RM, Mocan M, Inceu AI, Buda AP, Blendea D, Vlaicu SI (2022) Vulnerable atherosclerotic plaque: is there a molecular signature? Int J Mol Sci 23:13638. https://doi.org/10.3390/ijms232113638

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Thomas Ryan SJ, Faxon DP, Gunnar RM et al (1988) Special report guidelines for percutaneous transluminal coronary angioplasty a report of the American College of Cardiology/American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 78:486–502

    Article  Google Scholar 

  13. Vergallo R, Uemura S, Soeda T et al (2016) Prevalence and predictors of multiple coronary plaque ruptures: in vivo 3-Vessel optical coherence tomography imaging study. Arterioscler Thromb Vasc Biol 36:2229–2238. https://doi.org/10.1161/ATVBAHA.116.307891

    Article  CAS  PubMed  Google Scholar 

  14. Mohammad MA, Koul S, Egerstedt A et al (2020) Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction after ST-elevation myocardial infarction. Sci Rep 10:18663. https://doi.org/10.1038/s41598-020-75399-6

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

  15. Rogers JH (1987) Calretinin A gene for a novel calcium-binding protein expressed principally in neurons. J Cell Biol 105:1343–1353

    Article  CAS  PubMed  Google Scholar 

  16. Wörthmüller J, Blum W, Pecze L, Salicio V, Schwaller B (2018) Calretinin promotes invasiveness and EMT in malignant mesothelioma cells involving the activation of the FAK signaling pathway. Oncotarget 9:36256–36272

    Article  PubMed  PubMed Central  Google Scholar 

  17. Murphy JM, Jeong K, Steve Lim ST (2020) FAK family kinases in vascular diseases. Int J Mol Sci 21:3630. https://doi.org/10.3390/ijms21103630

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Murphy JM, Jeong K, Rodriguez YAR, Kim JH, Ahn EYE, Lim STS (2019) FAK and Pyk2 activity promote TNF-α and IL-1β-mediated pro-inflammatory gene expression and vascular inflammation. Sci Rep 9:7617. https://doi.org/10.1038/s41598-019-44098-2

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

  19. Yoshitomi R, Nakayama K, Yamashita S et al (2020) Plasma homocysteine concentration is associated with the expression level of folate receptor 3. Sci Rep 10:10283. https://doi.org/10.1038/s41598-020-67288-9

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

  20. Welch GN, Loscalzo J (1998) Homocysteine and atherothrombosis. N Engl J Med 338:1042–1050. https://doi.org/10.1056/NEJM199804093381507

    Article  CAS  PubMed  Google Scholar 

  21. Hida K, Wada J, Eguchi J et al (2005) Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U.S.A. 102:10610–10615. https://doi.org/10.1073/pnas.0504703102

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

  22. Esaki E, Adachi H, Hirai Y et al (2014) Serum vaspin levels are positively associated with carotid atherosclerosis in a general population. Atherosclerosis 233:248–252. https://doi.org/10.1016/j.atherosclerosis.2013.12.040

    Article  CAS  PubMed  Google Scholar 

  23. Nakatsuka A, Wada J, Iseda I et al (2013) Visceral adipose tissue-derived serine proteinase inhibitor inhibits apoptosis of endothelial cells as a ligand for the cell-surface GRP78/voltage-dependent anion channel complex. Circ Res 112:771–780. https://doi.org/10.1161/CIRCRESAHA.111.300049

    Article  CAS  PubMed  Google Scholar 

  24. Itoh N (2010) Hormone-like (endocrine) fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res 342:1–11. https://doi.org/10.1007/s00441-010-1024-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Fisher FM, Maratos-Flier E (2016) Understanding the physiology of FGF21. Annu Rev Physiol 78:223–241. https://doi.org/10.1146/annurev-physiol-021115-105339

    Article  CAS  PubMed  Google Scholar 

  26. Kralisch S, Tönjes A, Krause K et al (2013) Fibroblast growth factor-21 serum concentrations are associated with metabolic and hepatic markers in humans. J Endocrinol 216:135–143. https://doi.org/10.1530/JOE-12-0367

    Article  CAS  PubMed  Google Scholar 

  27. Gaich G, Chien JY, Fu H et al (2013) The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 18:333–340. https://doi.org/10.1016/j.cmet.2013.08.005

    Article  CAS  PubMed  Google Scholar 

  28. Zeng Z, Zheng Q, Chen J et al (2020) FGF21 mitigates atherosclerosis via inhibition of NLRP3 inflammasome-mediated vascular endothelial cells pyroptosis. Exp Cell Res 393:112108. https://doi.org/10.1016/j.yexcr.2020.112108

    Article  CAS  PubMed  Google Scholar 

  29. Li XH, Liu LZ, Chen L et al (2022) Aerobic exercise regulates FGF21 and NLRP3 inflammasome-mediated pyroptosis and inhibits atherosclerosis in mice. PLoS One 17:e0273527. https://doi.org/10.1371/journal.pone.0273527

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Dr. Ik-Kyung Jang’s research has been supported by “Mrs. Gillian Gray through the Allan Gray Fellowship Fund in Cardiology” and “Mukesh and Priti Chatter through the Chatter Foundation”.

Author information

Author notes

  1. Takayuki Niida and Haruhito Yuki have contributed equally to this work.

Authors and Affiliations

  1. Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Takayuki Niida, Haruhito Yuki, Keishi Suzuki, Daisuke Kinoshita, Daichi Fujimoto, Iris McNulty & Ik-Kyung Jang

  2. Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Hang Lee

  3. Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

    Kahraman Tanriverdi

  4. Interventional Cardiology Unit, New Tokyo Hospital, Chiba, Japan

    Akihiro Nakajima & Sunao Nakamura

  5. Allan and Gill Gray Professor of Medicine, Cardiology Division, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, GRB 800, Boston, MA, 02114, USA

    Ik-Kyung Jang

Authors
  1. Takayuki Niida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haruhito Yuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keishi Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daisuke Kinoshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daichi Fujimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akihiro Nakajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Iris McNulty
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hang Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kahraman Tanriverdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sunao Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ik-Kyung Jang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ik-Kyung Jang.

Ethics declarations

Conflict of interest

Dr. Ik-Kyung Jang has received educational grants from Abbott Vascular and a consulting fee from Svelte Medical Systems. Dr. Niida received a grant from the Japan Heart Foundation/Bayer Yakuhin Research Grant Abroad. The remaining authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 306.9 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Niida, T., Yuki, H., Suzuki, K. et al. Proteomics associated with coronary high-risk plaques by optical coherence tomography. J Thromb Thrombolysis 57, 204–211 (2024). https://doi.org/10.1007/s11239-023-02938-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-023-02938-z

Keywords

Search

Navigation